Robert E Landry insider trades: Cytokinetics (CYTK) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Robert reports to the SEC
Open-market buys and sales
38 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | CYTK | ↓ Sell | 1,000 | $72.13 | $72K | Direct | Sep 15, 2026 (0d) |
| Sep 11, 2026 | CYTK | ↓ Sell | 1,000 | $74.66 | $75K | Direct | Sep 11, 2026 (0d) |
| Aug 23, 2023 | REGN | ↓ Sell | 223 | $844.00 | $188K | Direct | Aug 25, 2023 (2d) |
| Mar 28, 2023 | REGN | ↓ Sell | 1,190 | $823.20 | $980K | Direct | Mar 29, 2023 (1d) |
| Feb 6, 2023 | REGN | ↓ Sell | 1,491 | $776.80 | $1.2M | Direct | Feb 7, 2023 (1d) |
| Dec 2, 2022 | REGN | ↓ Sell | 610 | $756.66 | $462K | Direct | Dec 2, 2022 (0d) |
| Nov 1, 2022 | REGN | ↓ Sell | 482 | $758.06 | $365K | Direct | Nov 2, 2022 (1d) |
| Oct 17, 2022 | REGN | ↓ Sell | 358 | $739.50 | $265K | Direct | Oct 18, 2022 (1d) |
| Apr 11, 2022 | REGN | ↓ Sell | 2,187 | $734.61 | $1.6M | Direct | Apr 11, 2022 (0d) |
| Apr 1, 2022 | REGN | ↓ Sell | 316 | $695.81 | $220K | Direct | Apr 1, 2022 (0d) |
| Mar 29, 2022 | REGN | ↓ Sell | 2,683 | $687.90 | $1.8M | Direct | Mar 30, 2022 (1d) |
| Mar 21, 2022 | REGN | ↓ Sell | 300 | $693.00 | $208K | Direct | Mar 23, 2022 (2d) |
| Mar 17, 2022 | REGN | ↓ Sell | 383 | $678.95 | $260K | Direct | Mar 18, 2022 (1d) |
| Dec 13, 2021 | REGN | ↓ Sell | 116 | $662.50 | $77K | Direct | Dec 14, 2021 (1d) |
| Dec 10, 2021 | REGN | ↓ Sell | 781 | $666.42 | $520K | Direct | Dec 10, 2021 (0d) |
| Nov 17, 2021 | REGN | ↓ Sell | 681 | $645.08 | $439K | Direct | Nov 18, 2021 (1d) |
| Aug 10, 2021 | REGN | ↓ Sell | 901 | $614.30 | $553K | Direct | Aug 10, 2021 (0d) |
| Aug 4, 2020 | REGN | ↓ Sell | 696 | $654.46 | $456K | Direct | Aug 5, 2020 (1d) |
| Jul 21, 2020 | REGN | ↓ Sell | 391 | $647.58 | $253K | Direct | Jul 22, 2020 (1d) |
| Jul 14, 2020 | REGN | ↓ Sell | 579 | $640.50 | $371K | Direct | Jul 14, 2020 (0d) |
| Jul 8, 2020 | REGN | ↓ Sell | 1,160 | $639.66 | $742K | Direct | Jul 9, 2020 (1d) |
| Jun 29, 2020 | REGN | ↓ Sell | 400 | $612.57 | $245K | Direct | Jun 30, 2020 (1d) |
| Jun 23, 2020 | REGN | ↓ Sell | 512 | $631.27 | $323K | Direct | Jun 24, 2020 (1d) |
| Jun 11, 2020 | REGN | ↓ Sell | 988 | $612.08 | $605K | Direct | Jun 12, 2020 (1d) |
| Jun 9, 2020 | REGN | ↓ Sell | 4,271 | $608.01 | $2.6M | Direct | Jun 10, 2020 (1d) |
| Apr 20, 2020 | REGN | ↓ Sell | 4,241 | $564.77 | $2.4M | Direct | Apr 20, 2020 (0d) |
| Apr 15, 2020 | REGN | ↓ Sell | 853 | $518.49 | $442K | Direct | Apr 16, 2020 (1d) |
| Apr 13, 2020 | REGN | ↓ Sell | 828 | $509.79 | $422K | Direct | Apr 13, 2020 (0d) |
| Apr 7, 2020 | REGN | ↓ Sell | 696 | $497.52 | $346K | Direct | Apr 8, 2020 (1d) |
| Apr 3, 2020 | REGN | ↓ Sell | 788 | $494.49 | $390K | Direct | Apr 3, 2020 (0d) |
| Apr 2, 2020 | REGN | ↓ Sell | 1,848 | $488.90 | $903K | Direct | Apr 3, 2020 (1d) |
| Feb 26, 2020 | REGN | ↓ Sell | 414 | $452.49 | $187K | Direct | Feb 26, 2020 (0d) |
| Feb 13, 2020 | REGN | ↓ Sell | 107 | $400.05 | $43K | Direct | Feb 14, 2020 (1d) |
| Sep 6, 2017 | REGN | ↓ Sell | 663 | $498.60 | $331K | Direct | Sep 6, 2017 (0d) |
| Aug 31, 2017 | REGN | ↓ Sell | 427 | $493.43 | $211K | Direct | Sep 1, 2017 (1d) |
| Aug 23, 2017 | REGN | ↓ Sell | 468 | $476.45 | $223K | Direct | Aug 24, 2017 (1d) |
| Aug 8, 2017 | REGN | ↓ Sell | 526 | $472.19 | $248K | Direct | Aug 9, 2017 (1d) |
| Aug 5, 2015 | REGN | ↓ Sell | 4,000 | $592.84 | $2.4M | Direct | Aug 6, 2015 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CYTK insiders
Open-market trades in the last 12 months
About Robert E Landry's insider trades
Robert E Landry is a director at Cytokinetics (CYTK). Since Aug 5, 2015, Robert has reported no open-market purchases and 38 sales worth $23.4M on SEC Form 4. In the last 12 months: 2 sales ($147K).
Their filings also include option exercises (45 filings), shares withheld for taxes (45 filings), grants and awards (15 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CYTK insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.